A Safety and Tolerability Study of ABT-126 in Elderly

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (544 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: safety tolerabilitytolerability andpharmacokineticsthe safetydose study
  Phrases that lowered it: healthy malemlcriteria healthycriteria historyassess the
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 10.2% (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Phase: 1 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 43 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Blinding: double (raises risk) · Design
• Minimum age: 65 (raises risk) · Who can join
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Keywords listed: 0 (lowers risk) · Design
• Sponsor's past trials: 59 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects NCT00968422 · started 2009 · scored riskier than 9% of active trials completed
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors NCT02220738 · started 2014 · scored riskier than 48% of active trials terminated
• A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease NCT01482845 · started 2011 · scored riskier than 69% of active trials completed
• Pharmacokinetic Study of ABT-126 in Healthy Volunteers NCT00959634 · started 2009 · scored riskier than 2% of active trials completed
• Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease NCT00948909 · started 2009 · scored riskier than 36% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.